XOMA Royalty (XOMA) Cash from Investing Activities Growth (1y) (2011 - 2026)
XOMA Royalty (XOMA) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 197.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197.89% |
| Dec 31, 2025 | 153.11% |
| Jun 30, 2025 | -438.89% |
| Mar 31, 2025 | 7.63% |
| Dec 31, 2024 | -761.06% |
| Sep 30, 2024 | 73.32% |
| Jun 30, 2024 | 231.55% |
| Mar 31, 2024 | -0.17% |
| Dec 31, 2023 | 136.14% |
| Sep 30, 2023 | 21,030.77% |
| Mar 31, 2023 | -44.68% |
| Dec 31, 2022 | -154.12% |
| Sep 30, 2022 | 100.37% |
| Mar 31, 2022 | 62.96% |
| Dec 31, 2021 | -2,900.00% |
| Dec 31, 2017 | 166.67% |
| Sep 30, 2017 | -103.86% |
| Jun 30, 2017 | 1,680.00% |
| Mar 31, 2017 | 2,722.58% |
| Dec 31, 2016 | -100.49% |